<span id="midArticle_start"/> Medigene AG :
<span id="midArticle_0"/>* Plans to issue new shares to finance its cancerimmunotherapy programme
<span id="midArticle_1"/>* Plans a cash capital increase with subscription rights forexisting shareholders by offering up to approx. 5.6 million newshares
<span id="midArticle_2"/> <span class="first-article-divide"/>* Resolved to settle payment in value of 700,000 euros forachievement of a milestone in clinical development of dendriticcell (DC) vaccines, as planned, in form of new shares
<span id="midArticle_3"/> <span class="second-article-divide"/>* Subscription price of new shares is planned to bedetermined on June 26, 2015
<span id="midArticle_4"/> <span class="third-article-divide"/>* Intends to increase its share capital of 14,051,815.00euros ($15.68 million) up to a total of 19,645,993.00 euros byissuing up to 5,594,178 new sharesSource text for Eikon: Further company coverage: ($1 = 0.8960 euros) (Gdynia Newsroom)
<span id="midArticle_5"/>
<span id="midArticle_0"/>* Plans to issue new shares to finance its cancerimmunotherapy programme
<span id="midArticle_1"/>* Plans a cash capital increase with subscription rights forexisting shareholders by offering up to approx. 5.6 million newshares
<span id="midArticle_2"/> <span class="first-article-divide"/>* Resolved to settle payment in value of 700,000 euros forachievement of a milestone in clinical development of dendriticcell (DC) vaccines, as planned, in form of new shares
<span id="midArticle_3"/> <span class="second-article-divide"/>* Subscription price of new shares is planned to bedetermined on June 26, 2015
<span id="midArticle_4"/> <span class="third-article-divide"/>* Intends to increase its share capital of 14,051,815.00euros ($15.68 million) up to a total of 19,645,993.00 euros byissuing up to 5,594,178 new sharesSource text for Eikon: Further company coverage: ($1 = 0.8960 euros) (Gdynia Newsroom)
<span id="midArticle_5"/>
via Smart Health Shop Forum http://ift.tt/1cPEqbK
No comments:
Post a Comment